NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration episode artwork

EPISODE · Jun 7, 2026 · 4 MIN

NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration

from Carl Haakon's Podcast

Episode 24 — 07 June 2026 NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Episode metadata supplied by the publisher feed · Published Jun 7, 2026

Embed this episode

Ready to play

NICE Diabetes Revolution, EU Device JCAs, Clinical Trial Acceleration

0:00 4:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Carl Haakon's Podcast?

This episode is 4 minutes long.

When was this Carl Haakon's Podcast episode published?

This episode was published on June 7, 2026.

Can I download this Carl Haakon's Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!